

Curriculum Vitae

Personal
information

Laura Díez Alonso

Work
experience

September 2023-present:

Clinical Assessor

The Spanish Agency Medicines and Medical Devices, Madrid, Spain

Activities: Clinical assessment of medicines (area: cardiovascular, respiratory, hematology)

2019-2022

Specialist in Immunology and predoctoral researcher

12 de Octubre University Hospital.I+12 Biomedical Research Foundation

Río Hortega Contract (Strategic Health Action 2020 ISCIII).

IP: Luis Álvarez-Vallina. Cancer Immunotherapy Unit.

2015-2019

Resident Internal Pharmacist

Clinical Immunology

12 de Octubre University Hospital.

Resident Internal
Pharmacist. 2015-2019
12 de Octubre
University Hospital.

Resident Internal Pharmacist. 2015-2019 12 de Octubre University Hospital.

Education and training

2019-present

PhD student, Biomedical Research Programme
Complutense University of Madrid, Madrid, Spain
"Novel cancer immunotherapy strategies"

2009-2014

Pharmacy Degree (grade: 8.13)
Complutense University of Madrid, Madrid, Spain

Additional information

Publications

[Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.](#)

Jiménez-Reinoso A, Tirado N, Martínez-Moreno A, Díaz VM, García-Peydró M, Hangiu O, **Díez-Alonso L**, Albitre Á, Penela P, Toribio ML, Menéndez P, Álvarez-Vallina L. J Immunother Cancer. 2022 Dec;10(12):e005333. doi: 10.1136/jitc-2022-005333.PMID: 36564128

[A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.](#)

Rubio-Pérez L, Lázaro-Gorines R, Harwood SL, Compte M, Navarro R, Tapia-Galisteo A, Bonet J, Blanco B, Lykkemark S, Ramírez-Fernández Á, Ferreras-Gutiérrez C, **Díez-Alonso L**, Segura-Tudela A, Hangiu O, Erce-Llamazares A, Blanco FJ, Santos C, Rodríguez-Peralto JL, Sanz L, Álvarez-Vallina L. Oncoimmunology. 2023;11(1):2054106. doi: 10.1080/2162402X.2023.2205336. eCollection 2023.PMID: 37114242

Share

[Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.](#)

Blanco B, Ramírez-Fernández Á, Bueno C, Argemí-Muntadas L, Fuentes P, Aguilar-Sopeña Ó, Gutiérrez-Agüera F, Zanetti SR, Tapia-Galisteo A, **Díez-Alonso L**, Castellà M, Marzal B, Betriu S, Harwood SL, Compte M, Lykkemark S, Erce-Llamazares A, Rubio-Pérez L, Jiménez-Reinoso A, Domínguez-Alonso C, Neves M, Muñoz-Ruiz C, Guedan S, Sanz L, Toribio ML, Roda-Navarro P, Juan M, Menéndez P, Álvarez-Vallina L. Cancer Immunol Res. 2022 Apr 1;10(4):498-511. doi: 10.1158/2326-6060.0853.PMID: 35362043

[Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.](#)

Ramírez-Fernández Á, Aguilar-Sopeña Ó, **Díez-Alonso L**, Segura-Tudela A, Domínguez-Alonso C, Roda-Navarro P, Álvarez-Vallina L, Blanco B. Oncoimmunology. 2023;11(1):2054106. doi: 10.1080/2162402X.2022.2054106. eCollection 2022.PMID: 35355682

[Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.](#)

Hangiu O, Compte M, Dinesen A, Navarro R, Tapia-Galisteo A, Mandrup OA, Erce-Llamazares A, Lázaro-Gorines R, Nehme-Álvarez D, Domínguez-Alonso C, Harwood SL, Rubio-Pérez L, Jiménez-Reinoso A, **Díez-Alonso L**, Blanco FJ, Sanz L, Howard KA, Álvarez-Vallina L. iScience. 2022 Aug 17;25(9):104958. doi: 10.1016/j.isci.2022.104958. eCollection 2022 Sep 16.PMID: 36072551

[Acquired Senescent T-Cell Phenotype Correlates with Clinical Severity in GATA Binding Protein 2-Deficient Patients.](#)

Ruiz-García R, Rodríguez-Vigil C, Marco FM, Gallego-Bustos F, Castro-Panete MJ, **Díez-Alonso L**, Muñoz-Ruiz C, Ruiz-Contreras J, Paz-Artal E, González-Granado S. Immunol. 2017 Jul 12;8:802. doi: 10.3389/fimmu.2017.00802. eCollection 2017.PMID: 28747912

Projects

Memberships

Other

